The Food and Drug Administration (FDA) has approved Somatuline Depot (lanreotide; Ipsen Biopharmaceuticals) injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in ...
The redesigned syringe includes a needle shield removal system and more stable plunger and thermoform tray with recessed areas designed to help prevent accidental plunger depression. The Food and Drug ...
Ipsen has won US approval for its oncology drug Somatuline Depot in a group of rare cancers of the neuroendocrine system. The US FDA backed the injectable treatment for use in adults with advanced or ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration (FDA) has approved a ...
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...
Sept 1 (Reuters) - Ipsen SA : * U.S. FDA has accepted and granted priority review of its supplemental new drug application (SNDA) for somatuline depot 120mg injection * Decision expected in early Q1 ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration (FDA) has approved a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback